These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 26214203)

  • 1. Warfarin Discontinuation in Patients With Unprovoked Venous Thromboembolism: A Large US Insurance Database Analysis.
    Xie L; Liu X; Phatak H; Mardekian J; Tan W; Baser O; Ramacciotti E
    Am J Ther; 2016; 23(6):e1744-e1753. PubMed ID: 26214203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI; Bunz TJ; Turpie AGG
    Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study.
    Larsen TB; Skjøth F; Kjældgaard JN; Lip GYH; Nielsen PB; Søgaard M
    Lancet Haematol; 2017 May; 4(5):e237-e244. PubMed ID: 28411120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-year adherence to warfarin treatment for venous thromboembolism in high-risk patients and its association with long-term risk of recurrent events.
    Chen SY; Wu N; Gulseth M; LaMori J; Bookhart BK; Boulanger L; Fields L; Schein J
    J Manag Care Pharm; 2013 May; 19(4):291-301. PubMed ID: 23627575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism: The PADIS-PE Randomized Clinical Trial.
    Couturaud F; Sanchez O; Pernod G; Mismetti P; Jego P; Duhamel E; Provost K; dit Sollier CB; Presles E; Castellant P; Parent F; Salaun PY; Bressollette L; Nonent M; Lorillon P; Girard P; Lacut K; Guégan M; Bosson JL; Laporte S; Leroyer C; Décousus H; Meyer G; Mottier D;
    JAMA; 2015 Jul; 314(1):31-40. PubMed ID: 26151264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of recurrent venous thromboembolism among deep vein thrombosis and pulmonary embolism patients treated with warfarin.
    Nordstrom BL; Evans MA; Murphy BR; Nutescu EA; Schein JR; Bookhart BK
    Curr Med Res Opin; 2015 Mar; 31(3):439-47. PubMed ID: 25495136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting.
    Willey VJ; Bullano MF; Hauch O; Reynolds M; Wygant G; Hoffman L; Mayzell G; Spyropoulos AC
    Clin Ther; 2004 Jul; 26(7):1149-59. PubMed ID: 15336480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
    Lee AYY; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
    JAMA; 2015 Aug; 314(7):677-686. PubMed ID: 26284719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Clinical and Economic Outcomes Associated with Warfarin Versus Apixaban in the Treatment of Patients with Venous Thromboembolism in a Large U.S. Commercial Claims Database.
    Guo JD; Rajpura J; Hlavacek P; Keshishian A; Sah J; Delinger R; Mu Q; Mardekian J; Russ C; Okano GJ; Rosenblatt L
    J Manag Care Spec Pharm; 2020 Aug; 26(8):1017-1026. PubMed ID: 32452277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discontinuation/Interruption of Warfarin Therapy in Patients with Nonvalvular Atrial Fibrillation.
    Spivey CA; Qiao Y; Liu X; Mardekian J; Parker RB; Phatak H; Claflin AB; Kachroo S; Abdulsattar Y; Chakrabarti A; Wang J
    J Manag Care Spec Pharm; 2015 Jul; 21(7):596-606. PubMed ID: 26108384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative risk of major bleeding with rivaroxaban and warfarin: Population-based cohort study of unprovoked venous thromboembolism.
    Kohn CG; Bunz TJ; Beyer-Westendorf J; Coleman CI
    Eur J Haematol; 2019 Feb; 102(2):143-149. PubMed ID: 30328143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Warfarin therapy in patients with venous thromboembolism: patterns of use and predictors of clinical outcomes.
    Deitelzweig SB; Lin J; Kreilick C; Hussein M; Battleman D
    Adv Ther; 2010 Sep; 27(9):623-33. PubMed ID: 20680533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of warfarin therapy among residents who developed venous thromboembolism in the nursing home.
    Reardon G; Pandya N; Nutescu EA; Lamori J; Damaraju CV; Schein J; Bookhart BK
    Am J Geriatr Pharmacother; 2012 Dec; 10(6):361-72. PubMed ID: 23217529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes after discontinuing anticoagulant therapy in patients with first unprovoked venous thromboembolism.
    Gabara C; Aibar J; Nishimoto Y; Yamashita Y; Prandoni P; Barnes GD; Bikdeli B; Jiménez D; Demelo-Rodríguez P; Peris ML; Nguyen ST; Monreal M;
    J Thromb Haemost; 2024 Aug; 22(8):2234-2246. PubMed ID: 38762019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients.
    Prandoni P; Noventa F; Ghirarduzzi A; Pengo V; Bernardi E; Pesavento R; Iotti M; Tormene D; Simioni P; Pagnan A
    Haematologica; 2007 Feb; 92(2):199-205. PubMed ID: 17296569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Healthcare costs associated with rivaroxaban or warfarin use for the treatment of venous thromboembolism.
    Coleman CI; Baugh C; Crivera C; Milentijevic D; Wang SW; Lu L; Nelson WW
    J Med Econ; 2017 Feb; 20(2):200-203. PubMed ID: 27780397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The long-term recurrence risk of patients with unprovoked venous thromboembolism: an observational cohort study.
    Kyrle PA; Kammer M; Eischer L; Weltermann A; Minar E; Hirschl M; Heinze G; Eichinger S
    J Thromb Haemost; 2016 Dec; 14(12):2402-2409. PubMed ID: 27696701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-utility of dabigatran etexilate compared with warfarin in treatment and extended anticoagulation of acute VTE in the UK.
    Jugrin AV; Ustyugova A; Urbich M; Lamotte M; Sunderland T
    Thromb Haemost; 2015 Oct; 114(4):778-92. PubMed ID: 26272227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of venous thromboembolism: adherence to guidelines and impact of physician knowledge, attitudes, and beliefs.
    Caprini JA; Tapson VF; Hyers TM; Waldo AL; Wittkowsky AK; Friedman R; Colgan KJ; Shillington AC;
    J Vasc Surg; 2005 Oct; 42(4):726-33. PubMed ID: 16242561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review.
    Gómez-Outes A; Suárez-Gea ML; Lecumberri R; Terleira-Fernández AI; Vargas-Castrillón E
    Vasc Health Risk Manag; 2014; 10():627-39. PubMed ID: 25404858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.